298 related articles for article (PubMed ID: 27260398)
1. How Can Gastric Cancer Molecular Profiling Guide Future Therapies?
Corso S; Giordano S
Trends Mol Med; 2016 Jul; 22(7):534-544. PubMed ID: 27260398
[TBL] [Abstract][Full Text] [Related]
2. Gastric Adenocarcinoma: An Update on Genomics, Immune System Modulations, and Targeted Therapy.
Lee J; Bass AJ; Ajani JA
Am Soc Clin Oncol Educ Book; 2016; 35():104-11. PubMed ID: 27249691
[TBL] [Abstract][Full Text] [Related]
3. Targeted therapy for gastric cancer: Current status and future directions (Review).
Yuan DD; Zhu ZX; Zhang X; Liu J
Oncol Rep; 2016 Mar; 35(3):1245-54. PubMed ID: 26718131
[TBL] [Abstract][Full Text] [Related]
4. Challenges in molecular targeted therapy for gastric cancer: considerations for efficacy and safety.
Narita Y; Muro K
Expert Opin Drug Saf; 2017 Mar; 16(3):319-327. PubMed ID: 27976952
[TBL] [Abstract][Full Text] [Related]
5. Targeted therapies in metastatic gastric cancer: Current knowledge and future perspectives.
Pellino A; Riello E; Nappo F; Brignola S; Murgioni S; Djaballah SA; Lonardi S; Zagonel V; Rugge M; Loupakis F; Fassan M
World J Gastroenterol; 2019 Oct; 25(38):5773-5788. PubMed ID: 31636471
[TBL] [Abstract][Full Text] [Related]
6. Targeted therapy in advanced gastric carcinoma: the future is beginning.
Schinzari G; Cassano A; Orlandi A; Basso M; Barone C
Curr Med Chem; 2014; 21(8):1026-38. PubMed ID: 24304282
[TBL] [Abstract][Full Text] [Related]
7. Ramucirumab in HER-2-positive gastroesophageal adenocarcinoma: an argument for overcoming trastuzumab resistance.
Tehfe M; Tabchi S; Laterza MM; De Vita F
Future Oncol; 2018 Feb; 14(3):223-228. PubMed ID: 29318901
[TBL] [Abstract][Full Text] [Related]
8. Progress and challenges in HER2-positive gastroesophageal adenocarcinoma.
Zhao D; Klempner SJ; Chao J
J Hematol Oncol; 2019 May; 12(1):50. PubMed ID: 31101074
[TBL] [Abstract][Full Text] [Related]
9. Translating gastric cancer genomics into targeted therapies.
Ang YL; Yong WP; Tan P
Crit Rev Oncol Hematol; 2016 Apr; 100():141-6. PubMed ID: 26947813
[TBL] [Abstract][Full Text] [Related]
10. Her-2/neu gene amplification and over-expression in stomach and esophageal adenocarcinoma: from pathology to treatment.
Maresch J; Schoppmann SF; Thallinger CM; Zielinski CC; Hejna M
Crit Rev Oncol Hematol; 2012 Jun; 82(3):310-22. PubMed ID: 21783379
[TBL] [Abstract][Full Text] [Related]
11. Gastric Carcinoma at the Era of Targeted Therapies.
Dreanic J; Dhooge M; Sion E; Brezault C; Chaussade S; Coriat R
Curr Drug Targets; 2016; 17(15):1818-1826. PubMed ID: 25944013
[TBL] [Abstract][Full Text] [Related]
12. What's New in Gastric Cancer: The Therapeutic Implications of Molecular Classifications and Future Perspectives.
Tirino G; Pompella L; Petrillo A; Laterza MM; Pappalardo A; Caterino M; Orditura M; Ciardiello F; Galizia G; De Vita F
Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30205505
[TBL] [Abstract][Full Text] [Related]
13. Targeting HER 2 and angiogenesis in gastric cancer.
Jomrich G; Schoppmann SF
Expert Rev Anticancer Ther; 2016; 16(1):111-22. PubMed ID: 26567753
[TBL] [Abstract][Full Text] [Related]
14. Advanced HER2-positive gastric cancer: current and future targeted therapies.
Pazo Cid RA; Antón A
Crit Rev Oncol Hematol; 2013 Mar; 85(3):350-62. PubMed ID: 23021388
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Trastuzumab Anti-Tumor Efficacy and its Correlation with HER-2 Status in Patient-Derived Gastric Adenocarcinoma Xenograft Models.
Chen H; Ye Q; Lv J; Ye P; Sun Y; Fan S; Su X; Gavine P; Yin X
Pathol Oncol Res; 2015 Sep; 21(4):947-55. PubMed ID: 25749810
[TBL] [Abstract][Full Text] [Related]
16. Personalized medicine in gastric cancer: Where are we and where are we going?
Jácome AA; Coutinho AK; Lima EM; Andrade AC; Dos Santos JS
World J Gastroenterol; 2016 Jan; 22(3):1160-71. PubMed ID: 26811654
[TBL] [Abstract][Full Text] [Related]
17. [HER2 testing and targeted therapy in advanced gastric cancer].
Höhler T; Rüschoff J; Ridwelski K; Moehler M
Onkologie; 2010; 33 Suppl 4():26-30. PubMed ID: 20431310
[TBL] [Abstract][Full Text] [Related]
18. HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications.
Hechtman JF; Polydorides AD
Arch Pathol Lab Med; 2012 Jun; 136(6):691-7. PubMed ID: 22646280
[TBL] [Abstract][Full Text] [Related]
19. Targeted therapy for gastric cancer.
Smyth EC; Cunningham D
Curr Treat Options Oncol; 2012 Sep; 13(3):377-89. PubMed ID: 22552927
[TBL] [Abstract][Full Text] [Related]
20. Targeted HER2 treatment in advanced gastric cancer.
Jørgensen JT
Oncology; 2010; 78(1):26-33. PubMed ID: 20185938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]